Needham offers Biogen a buy score, forecasts huge rally in spite of debate around Alzheimer's drug

The rollout of Aduhelm is dealing with "near-term challenges," according to Biogen.


News and digital media editor, writer, and communications specialist. Passionate about social justice, equity, and wellness. Covering the news, viewing it differently.

Related Articles

Back to top button

Adblock Detected

Please turn off the Adblocker